News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News April 13, 2026
Gibson Dunn Advises Assertio on Sale to Garda Therapeutics and on Sale of U.S. Sales and Distribution Rights for Portfolio of Seven Branded Products to Cosette Pharmaceuticals
Gibson Dunn is advising Assertio Holdings on its sale to Garda Therapeutics.
Firm News April 7, 2026
Gibson Dunn Advises Korsana Biosciences on Merger with Cyclerion Therapeutics
Gibson Dunn is advising Korsana Biosciences on its merger with Cyclerion Therapeutics, Inc. and concurrent $380 million financing.
Client Alert March 11, 2026
Royalty Finance in Life Sciences – Market Update 2026
This Royalty Finance Market Update provides an analysis of publicly reported royalty finance transactions for 2020 through 2025 in the life sciences sector, focusing on both traditional and synthetic royalty transactions.
Client Alert March 3, 2026
When Should Companies Disclose Drug Safety Risks?
Our lawyers discuss a recent ruling highlighting when companies should disclose drug safety risks.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc. The all-stock transaction is valued at approximately $300 million.
Firm News February 27, 2026
Gibson Dunn Advised Shareholders in Connection with Sale of Aicuris to Asahi Kasei
Gibson Dunn advised the shareholders in connection with the sale of Aicuris Anti-infective Cures AG to Asahi Kasei, through its subsidiary Veloxis Pharmaceuticals, Inc.
In the Media February 26, 2026
Ryan Murr and Charlotte Jacobsen Interviewed by Law360 After Team Named a Life Sciences Group of the Year
Partners Ryan Murr and Charlotte Jacobsen were interviewed by Law360 after the team was named a Life Sciences Group of the Year. They discussed recent successes and the reasons why the team’s work stands out for clients.
Firm News February 17, 2026
Gibson Dunn Advised Galecto on Public Offering of Common Stock
Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.